Patents by Inventor Riccardo Cortese
Riccardo Cortese has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10544192Abstract: The present invention relates to novel adenovirus strains with an improved seroprevalence. In one aspect, the present invention relates to isolated polypeptides of adenoviral capsid proteins such as hexon, penton and fiber protein and fragments thereof and polynucleotides encoding the same. Also provided is a vector comprising the isolated polynucleotide according to the invention and adenoviruses comprising the isolated polynucleotides or polypeptides according to the invention and a pharmaceutical composition comprising said vector, adenovirus, polypeptide and/or polynucleotide. The invention also relates to the use of the isolated polypeptides, the isolated polypeptides, the vector, the adenoviruses and/or the pharmaceutical composition for the therapy or prophylaxis of a disease.Type: GrantFiled: June 15, 2017Date of Patent: January 28, 2020Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Stefano Colloca, Alfredo Nicosia, Riccardo Cortese, Sr., Virginia Ammendola, Maria Ambrosio
-
Publication number: 20190338014Abstract: The present application provides inter alia a fusion protein comprising a polypeptide wherein the polypeptide consists of a fragment of invariant chain which is operably linked to an antigenic sequence and wherein the fragment of invariant chain consists of a portion of residues 17-97 of SEQ ID NO: 1, wherein the portion comprises at least 5 contiguous residues from residues 77-92 of SEQ ID NO: 1.Type: ApplicationFiled: August 23, 2017Publication date: November 7, 2019Applicants: GLAXOSMITHKLINE BIOLOGICALS SA, UNIVERSITY OF COPENHAGENInventors: Maria Rosaria BASSI, Riccardo CORTESE, Anna Morena D'ALISE, Antonella FOLGORI, Peter Johannes HOLST, Alfredo NICOSIA
-
Publication number: 20180216081Abstract: There is provided adenoviral vectors encoding a mycobacterial antigen derived from a chimp adenovirus, and to related aspects.Type: ApplicationFiled: July 25, 2016Publication date: August 2, 2018Applicant: GLAXOSMITHKLINE BIOLOGICALS, SAInventors: Stefano COLLOCA, Virginia AMMENDOLA, Fabiana GRAZIOLI, Alessandra VITELLI, Alfredo NICOSIA, Riccardo CORTESE
-
Publication number: 20180170972Abstract: There is provided inter alia an isolated polynucleotide, wherein the polynucleotide encodes a polypeptide selected from the group consisting of: (a) a polypeptide having the amino acid sequence according to SEQ ID NO: 1, (b) a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 1, wherein the functional derivative has an amino acid sequence which is at least 80% identical over its entire length to the amino acid sequence of SEQ ID NO: 1, and (c) a polypeptide having the amino acid sequence according to SEQ ID NO: 3.Type: ApplicationFiled: June 10, 2016Publication date: June 21, 2018Applicant: GLAXOSMITHKLINE BIOLOGICALS, SAInventors: Stefano COLLOCA, Virginia AMMENDOLA, Fabiana GRAZIOLI, Alessandra Franz VITELLI, Alfredo NICOSIA, Riccardo CORTESE
-
Publication number: 20180125968Abstract: The present application relates to novel administration regimens for poxviral vectors comprising nucleic acid constructs encoding antigenic proteins and invariant chains. In particular the use of said poxviral vectors for priming or for boosting an immune response is disclosed.Type: ApplicationFiled: December 20, 2017Publication date: May 10, 2018Applicant: GLAXOSMITHKLINE BIOLOGICALS, SAInventors: Stefano COLLOCA, Riccardo CORTESE, Antonella FOLGORI, Alfredo NICOSIA
-
Publication number: 20180057540Abstract: The present invention relates to novel adenovirus strains with an improved seroprevalence. In one aspect, the present invention relates to isolated polypeptides of adenoviral capsid proteins such as hexon, penton and fiber protein and fragments thereof and polynucleotides encoding the same. Also provided is a vector comprising the isolated polynucleotide according to the invention and adenoviruses comprising the isolated polynucleotides or polypeptides according to the invention and a pharmaceutical composition comprising said vector, adenovirus, polypeptide and/or polynucleotide. The invention also relates to the use of the isolated polypeptides, the isolated polypeptides, the vector, the adenoviruses and/or the pharmaceutical composition for the therapy or prophylaxis of a disease.Type: ApplicationFiled: June 15, 2017Publication date: March 1, 2018Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Stefano Colloca, Alfredo Nicosia, Riccardo Cortese, Sr., Virginia Ammendola, Maria Ambrosio
-
Patent number: 9895431Abstract: The invention provides recombinant adenoviral vectors which are capable of eliciting immunity against the pre-erythrocytic stage of the life cycle of the malaria parasite. In particular, the invention provides a recombinant, replication deficient simian adenoviral vector which encodes an antigen comprising the thrombospondin-related adhesion protein (TRAP), and also immunogenic compositions (e.g. vaccines) comprising the vector and methods of using such compositions.Type: GrantFiled: April 10, 2008Date of Patent: February 20, 2018Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Arturo Reyes, Adrian Hill, Geraldine O'Hara, Stefano Colloca, Riccardo Cortese
-
Publication number: 20170333550Abstract: The present application relates to novel administration regimens for poxviral vectors comprising nucleic acid constructs encoding antigenic proteins and invariant chains. In particular the use of said poxviral vectors for priming or for boosting an immune response is disclosed.Type: ApplicationFiled: March 17, 2017Publication date: November 23, 2017Applicant: GLAXOSMITHKLINE BIOLOGICALS, SAInventors: Stefano COLLOCA, Riccardo CORTESE, Antonella FOLGORI, Alfredo NICOSIA
-
Patent number: 9718863Abstract: The present invention relates to novel adenovirus strains with an improved seroprevalence. In one aspect, the present invention relates to isolated polypeptides of adenoviral capsid proteins such as hexon, penton and fiber protein and fragments thereof and polynucleotides encoding the same. Also provided is a vector comprising the isolated polynucleotide according to the invention and adenoviruses comprising the isolated polynucleotides or polypeptides according to the invention and a pharmaceutical composition comprising said vector, adenovirus, polypeptide and/or polynucleotide. The invention also relates to the use of the isolated polynucleotides, the isolated polypeptides, the vector, the adenoviruses and/or the pharmaceutical composition for the therapy or prophylaxis of a disease.Type: GrantFiled: February 6, 2010Date of Patent: August 1, 2017Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Stefano Colloca, Alfredo Nicosia, Riccardo Cortese, Virginia Ammendola, Maria Ambrosio
-
Publication number: 20170044571Abstract: This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).Type: ApplicationFiled: October 31, 2016Publication date: February 16, 2017Inventors: Nancy J. Sullivan, Gary J Nabel, Clement Asiedu, Cheng Cheng, Alfredo Nicosia, Riccardo Cortese, Virginia Ammendola, Stefano Colloca
-
Patent number: 9526777Abstract: This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebola virus (EBOV) or Marburg virus (MARV).Type: GrantFiled: April 15, 2011Date of Patent: December 27, 2016Assignees: The United States of America as Represented by the Department of Health and Human Services, Glaxosmithkline Biologicals SAInventors: Nancy J. Sullivan, Gary J. Nabel, Clement Asiedu, Cheng Cheng, Alfredo Nicosia, Riccardo Cortese, Virginia Ammendola, Stefano Colloca
-
Publication number: 20160000904Abstract: The present application relates to novel administration regimens for poxviral vectors comprising nucleic acid constructs encoding antigenic proteins and invariant chains. In particular the use of said poxviral vectors for priming or for boosting an immune response is disclosed.Type: ApplicationFiled: March 14, 2014Publication date: January 7, 2016Inventors: Stefano COLLOCA, Riccardo CORTESE, Antonella FOLGORI, Alfredo NICOSIA
-
Publication number: 20140141042Abstract: The invention relates to an expression system comprising polynucleotides encoding proteins, wherein the expression system comprises a first polynucleotide encoding at least one protein, peptide or variant thereof, which induces a T cell response, and a second polynucleotide encoding at least one protein peptide or variant thereof, which induces an anti-pathogenic B cell response. The invention further relates to protein mixtures encoded by the expression system and cells comprising the expression system or the protein mixture and pharmaceutical compositions comprising the expression system or the protein mixture. The expression system, polynucleotides, proteins, cells, and pharmaceutical compositions are useful in the prophylaxis or treatment of infections. The invention further relates to nucleotide constructs which comprises, essentially consists or consists of a polynucleotide encoding a modified influenza hemagglutinin (HA).Type: ApplicationFiled: December 30, 2011Publication date: May 22, 2014Applicant: OKAIROS AGInventors: Alessandra Vitelli, Alfredo Nicosia, Riccardo Cortese
-
Publication number: 20130150563Abstract: The present invention relates to novel lipid-conjugated antibodies for use in the treatment or the prevention of diseases, including but not limited to cancer, metabolic diseases including but not limited to hyperglycemia and diabetes, obesity, hypertension, hypercholesterolemia, allergy, asthma, Alzheimer's disease, and infectious diseases including but not limited to diseases caused by viruses, bacteria and fungi.Type: ApplicationFiled: July 8, 2011Publication date: June 13, 2013Applicant: JV BIO SRLInventors: Antonello Pessi, Alfredo Nicosia, Riccardo Cortese
-
Publication number: 20130101618Abstract: This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).Type: ApplicationFiled: April 15, 2011Publication date: April 25, 2013Applicants: OKAIROS AG, TheGovernmentof the UnitedStatesof America asRepre -sentedby theSecretaryoftheDept.ofHealth&HumanSerInventors: Nancy J. Sullivan, Gary J. Nabel, Clement Asiedu, Cheng Cheng, Alfredo Nicosia, Riccardo Cortese, Virginia Ammendola, Stefano Colloca
-
Patent number: 8142794Abstract: The present invention features Ad6 vectors and a nucleic acid encoding a Met-NS3-NS4A-NS4B-NS5A-NS5B polypeptide containing an inactive NS5B RNA-dependent RNA polymerase region. The nucleic acid is particularly useful as a component of an adenovector or DNA plasmid vaccine providing a broad range of antigens for generating an HCV specific cell mediated immune (CMI) response against HCV.Type: GrantFiled: March 3, 2009Date of Patent: March 27, 2012Assignee: Merck Sharp & Dohme Corp.Inventors: Emilio A. Emini, David C. Kaslow, Andrew J. Bett, John W. Shiver, Alfredo Nicosia, Armin Lahm, Alessandra Luzzago, Riccardo Cortese, Stefano Colloca
-
Publication number: 20120027788Abstract: The present invention relates to novel adenovirus strains with an improved sero-prevalence. In one aspect, the present invention relates to isolated polypeptides of adenoviral capsid proteins such as hexon, penton and fiber protein and fragments thereof and polynucleotides encoding the same. Also provided is a vector comprising the isolated polynucleotide according to the invention and adenoviruses comprising the isolated polynucleotides or polypeptides according to the invention and a pharmaceutical composition comprising said vector, adenovirus, polypeptide and/or polynucleotide. The invention also relates to the use of the isolated polynucleotides, the isolated polypeptides, the vector, the adenoviruses and/or the pharmaceutical composition for the therapy or prophylaxis of a disease.Type: ApplicationFiled: February 6, 2010Publication date: February 2, 2012Inventors: Stefano Colloca, Alfredo Nicosia, Riccardo Cortese, Virginia Ammendola, Maria Ambrosio
-
Publication number: 20110129498Abstract: The present invention relates to CD81-binding peptides of the hepatitis virus C(HCV) E2 glycoprotein, which are devoid of or mutated within the amino-terminal 27 amino acids of the mature E2 envelope glycoprotein, or variant thereof which retains the ability to bind to CD81. Furthermore, the present invention provides polypeptides comprising said CD81-binding peptide, polynucleotides encoding the CD81-binding peptide, and expression cassettes and vectors comprising the polynucleotide of the invention. Moreover, the present invention relates to compositions comprising the CD81-binding peptide, the polynucleotide encoding the CD81-binding peptide, the expression cassette, or the vector, and an adjuvant. Furthermore, the present invention provides a pharmaceutical composition comprising the CD81-binding peptide, the polynucleotide, the expression cassette, the vector, or the composition of the invention, and a pharmaceutically acceptable excipient, carrier, or diluent.Type: ApplicationFiled: June 3, 2009Publication date: June 2, 2011Applicant: OKAIROS AGInventors: Riccardo Cortese, Alfredo Nicosia
-
Patent number: 7928193Abstract: The present invention features antigen binding protein that bind to a SR-BI target region identified herein as a region involved in HCV E2 binding. Identified target regions are regions bound by a single-chain antibody of SEQ ID NOs: 1, 2, 3 or 4.Type: GrantFiled: July 1, 2005Date of Patent: April 19, 2011Assignee: Istituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A.Inventors: Riccardo Cortese, Alessandra Luzzago, Alfredo Nicosia, Alessandra Vitelli
-
Patent number: 7598362Abstract: The present invention features Ad6 vectors and a nucleic acid encoding a Met-NS3-NS4A-NS4B-NS5A-NS5B polypeptide containing an inactive NS5B RNA-dependent RNA polymerase region. The nucleic acid is particularly useful as a component of an adenovector or DNA plasmid vaccine providing a broad range of antigens for generating an HCV specific cell mediated immune (CMI) response against HCV.Type: GrantFiled: October 10, 2002Date of Patent: October 6, 2009Assignees: Merck & Co., Inc., Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.p.A.Inventors: Emilio A. Emini, David C. Kaslow, Andrew J. Bett, John W. Shiver, Alfredo Nicosia, Armin Lahm, Alessandra Luzzago, Riccardo Cortese, Stefano Colloca